Document is current
Any future updates will be listed below
-
Authors
Ueda, Keisuke https://orcid.org/0000-0003-0235-4323
Porter, Christopher J. H. https://orcid.org/0000-0003-3474-7551
Goodwin, Aaron https://orcid.org/0009-0005-1209-9129
Taylor, Lynne S. https://orcid.org/0000-0002-4568-6021
- License Information
-
More Information
Article History
Accepted: 19 February 2026
First Online: 2 April 2026
Competing interests
: C.J.H.P. is an inventor on intellectual property (IP) related to a triglyceride-mimetic prodrug technology that is briefly described in this Perspective and was licensed from Monash University to Seaport Therapeutics. L.S.T. has served as a consultant or paid speaker, may own shares or has received recent research funding from the following companies whose products are mentioned in this submission: Pfizer, Eli Lilly, AstraZeneca, Bristol Myers Squibb, Johnson and Johnson, AbbVie and Merck. The remaining authors declare no competing interests.
